Secondary Logo

Journal Logo

Basic Science

Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome

Nakiwala, Justine K. BSc*,†,‡; Walker, Naomi F. MRCP, PhD*,§; Diedrich, Collin R. PhD*,‖; Worodria, William MD; Meintjes, Graeme MD, PhD*,#; Wilkinson, Robert J. FRCP, PhD*,#,**; Mayanja-Kizza, Harriet MBChB, MMed, MSc, FACP; Colebunders, Robert MD, PhD†,††; Kestens, Luc PhD†,‡; Wilkinson, Katalin A. PhD*,**; Lowe, David M. PhD*,#,‡‡

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: February 1, 2018 - Volume 77 - Issue 2 - p 221-229
doi: 10.1097/QAI.0000000000001582

Abstract

Erratum

In the article by Nakiwala et al, appearing in JAIDS: Journal of Acquired Immune Deficiency Syndromes, Vol. 77, No. 2, pp. 221-229 entitled, “Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome”, the first author’s degree is listed incorrectly, it should have appeared as Justine K. Nakiwala, MSc.

JAIDS Journal of Acquired Immune Deficiency Syndromes. 78(2):e13, June 1, 2018.

INTRODUCTION

When patients with HIV-associated tuberculosis (TB) begin antiretroviral therapy (ART), approximately 18% develop TB-associated immune reconstitution inflammatory syndrome (TB-IRIS).1 TB-IRIS is an exaggerated immune response to M. tuberculosis antigens associated with reconstitution of the immune system. It is characterized by excessive inflammatory responses and deterioration in clinical status.1,2

According to the International Network for the Study of HIV-associated IRIS (INSHI) case definitions, 2 forms of TB-IRIS exist: “paradoxical” (clinical worsening of a patient on TB treatment after starting ART) and “unmasking” (undiagnosed TB becoming apparent after starting ART).3

TB-IRIS has been associated with perturbations in both the adaptive and innate immune systems.4,5 These include increased secretion of neutrophil-associated mediators such as S100A8/A9 and matrix metalloproteinases,6–8 perforin and granzyme B by CD4+ T cells,9 higher expression and imbalance of C1Q and C1-inhibitor (complement system),10 activation of monocytes,11 inflammasome and Toll-like receptor signaling12,13, as well as elevated chemokine and cytokine production14–16 with a particular role for the IL-10 family.17 Although rapid changes in CD4+ T-cell count have long been associated with all forms of IRIS, recent research has focused on these latter phenomena of inflammasome activation and release of soluble mediators from innate cells.4,12 However, the clinical syndromes associated with TB-IRIS, especially suppurative lymphadenitis and abscess formation, implicate neutrophils as critical effector cells mobilized by these inflammatory signals.

To gain further understanding into the biology of TB-IRIS, we recruited and prospectively followed patients with HIV-associated TB (HIV+TB+) at risk of developing IRIS at 2 clinical sites, in Uganda and South Africa. First, we conducted an assessment of gene expression in putative pathways. On the basis of previous research summarized above, we chose to study the T-cell receptor, cytokine genes including the IL-10 pathway17, and the inflammasome.12,13 Subsequently, in a separate cohort, we performed functional assays chosen on the basis of genes that were overexpressed in patients with IRIS versus controls; these experiments focused on neutrophils which, although implicated,6 have not been extensively studied before in TB-IRIS.

MATERIALS AND METHODS

Patient Recruitment and Study Visits

Cohort 1

Patients with a confirmed diagnosis of both HIV and TB, on TB treatment [for a median (IQR) of 40 (24–59) days] and who were eligible for ART initiation according to the July 2008 Ugandan National Treatment Guidelines (CD4 count <250 cells/µL), were recruited in 2009 at Mulago National Tuberculosis and Leprosy Clinic and the Infectious Diseases Institute in Kampala for gene expression studies, as previously described18; see Supplemental Digital Content Table 1, https://links.lww.com/QAI/B91. Patients were reviewed at week 0 (before ART initiation), week 2, and months 1–12 (after ART initiation). Patients who developed TB-IRIS (cases) were defined according to the INSHI clinical case definitions3 and were matched by age (<10 years difference between patients), CD4 cell count before ART initiation [mean (SD) difference, 5.3 (6.8) cells/µL], and sex with those who did not develop TB-IRIS (non-IRIS controls). Sampling at the IRIS time point was performed before patients received corticosteroids. All patients provided written informed consent. The Uganda National Council of Science and Technology, Makerere Faculty of Medicine Ethics Committee (IRB-Makerere-05_2007), Infectious Disease Scientific Review Committee, University of Antwerp Ethics Committee, and the Institute of Tropical Medicine, Antwerp, Belgium (CME_UZA_7/29/157) approved the study.

Cohort 2

Recruitment of patients for neutrophil studies took place in Cape Town, South Africa as part of the longitudinal tissue destruction in tuberculosis 2 study (Supplemental Digital Content Table 1, https://links.lww.com/QAI/B91). Patients were recruited in 2013 at Ubuntu clinic, a primary care HIV treatment clinic in site B, Khayelitsha. HIV-infected patients at high risk of developing TB-IRIS (CD4 count <200 cells/µL at enrollment) were followed up during anti-TB treatment and initiation of ART until 12 weeks of ART. Samples for neutrophil studies were collected at ART initiation (week 0), week 2, and week 4 of ART. TB-IRIS diagnosis was made retrospectively after week 12 by a consensus panel using the INSHI case definition; controls (non-IRIS) were those patients who were also sampled at ART initiation and week 2/week 4 follow-up visits but did not develop the syndrome.3 At the IRIS/week 2 time point, 2 TB-IRIS and 1 non-IRIS control were receiving corticosteroids. Ethical approval was obtained from the Faculty of Health Sciences Human Research Ethics Committee, University of Cape Town (HREC REF: 516/2011); all patients provided written informed consent.

Samples for detailed analysis were available from 34 patients in cohort 1 (17 cases and 17 controls) and 29 patients in cohort 2 (18 cases and 11 controls). Supplemental Digital Content Figure 1, https://links.lww.com/QAI/B91 summarizes the study design.

Sample Collection and Processing

For cohort 1, venous blood (30–40 mL) was collected in EDTA tubes (BD Pharmingen, Franklin Lakes, NJ) at week 0 and week 2 after initiation of ART. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque gradient centrifugation and cryopreserved for further processing (see below). For cohort 2, blood samples (30–40 mL) were collected in sodium heparin vacutainers (BD Pharmingen) at weeks 0, 2, and 4 after initiation of ART and were processed for plasma generation within 2 hours of collection; an aliquot (1 mL) of blood was removed for functional assays as described below.

nCounter Gene Expression Analysis

RNA was extracted from PBMC using standard techniques (Supplemental Digital Content Methods, https://links.lww.com/QAI/B91). Probeset sequences for the gene sets of interest (T-cell receptors, the inflammasome, IL-10 pathway, and cytokines; 148 genes in total) are shown in Supplemental Digital Content Table 2, https://links.lww.com/QAI/B91.

Determination of Neutrophil Activation and Degranulation

We investigated neutrophil activation in whole blood by flow cytometry, measuring cell surface expression of CD11b, CD16, CD62L, CD66a,c,e19, and IL-8RA. An aliquot of whole blood was stained on ice with CD11b-PE-Cy7, CD16-APC-H7, CD62L-FITC, CD66a,c,e-PE, IL-8 RA-APC (BD Pharmingen), and viability dye (eFluor 450; eBiosciences, San Diego, CA or ViViD; Invitrogen, Carlsbad, CA). After washing, the stained sample was fixed in 2% paraformaldehyde and acquired on a Becton Dickinson Fortessa flow cytometer (BD Biosciences). Data analysis was performed with FlowJo software (FlowJo 10.1r5; Tree Star, Ashland, OR) using the gating strategy in Supplemental Digital Content Figure 2, https://links.lww.com/QAI/B91.

Determination of Neutrophil Elastase and Human Neutrophil Peptides in Plasma

Neutrophil elastase and human neutrophil peptides (HNP1-3) plasma concentrations were quantified using enzyme-linked immunosorbent assay according to the manufacturer's instructions (Hycult Biotech, Uden, The Netherlands). Assays were performed in duplicate. The sensitivity for neutrophil elastase was 0.67 ng/mL and for HNP1-3 was 4.25 pg/mL. The elastase assay detects both free and complexed elastase.

Immunohistochemistry Staining of Lymph Nodes

Patient selection, lymph node (LN) preparation, and immunohistochemistry were performed as previously described20 and summarized in Supplemental Digital Content Methods, https://links.lww.com/QAI/B91.

Statistical Analysis

Comparison between 2 groups was performed using t tests (unpaired for IRIS versus non-IRIS comparisons or paired for within-group comparisons between baseline and week 2), Mann–Whitney U test or Wilcoxon test for continuous variables, and Fisher exact tests for categorical variables. Statistics were performed using GraphPad Prism Version 7.0 (La Jolla, CA) and Qlucore Omics Explorer version 3.2. (Lund, Sweden) Significance was inferred below a 2-tailed P value of 0.05.

Gene expression analysis to identify discriminating transcripts between the groups [based on P value <0.05 and q value (false discovery rate–adjusted P value) <0.1] was performed using Qlucore Omics Explorer and displayed on a heatmap. The IRIS (pink) and non-IRIS (blue) patients (columns) and genes (rows) were ordered using principal component analysis (PCA) and R statistic, respectively. Gene expression at the week 2 time point on the heatmap was classified as high or low (relative to the entire cohort) if colored red and green, respectively. A PCA plot, with the projection score and variance filtering set at 0.38 and 0.43, respectively, was used to detect strong signals within the data on gene transcript abundance. PCA identifies the major vectors (“components”) which differentiate multiparameter data sets. The genes were colored according to their R statistic with green and red if higher in non-IRIS controls or IRIS patients, respectively, and the distance between individual genes reflects their correlation coefficient.

RESULTS

Patient Characteristics

Supplemental Digital Content Table 1, https://links.lww.com/QAI/B91 summarizes demographic and basic laboratory data for both cohorts. At ART initiation, there were no statistical differences in patient characteristics between those who subsequently developed IRIS and those who did not. The median (IQR) time to IRIS presentation across both studies was 14 (10–15) days.

RNA Analysis Reveals Higher Expression of Genes Implicated in Neutrophilic Inflammation in Patients With TB-IRIS Compared With Controls

We used NanoString nCounter technology to ascertain gene expression in PBMC of patients with IRIS and non-IRIS patients at the IRIS timepoint (median of 14 days) or after 2 weeks of ART in controls. The nCounter gene expression values obtained were log2 transformed before analysis to normalize data as per standard transcriptomic analytical pathways; a false discovery rate (q value) of 0.1 was applied to account for multiple comparisons. A heatmap to visualize the pattern of transcript abundance in patients with IRIS and non-IRIS controls revealed over 70 discriminating transcripts with modest clustering of patients with IRIS (pink) and non-IRIS controls (blue); there was generally lower gene expression (green) in the patients with IRIS compared with the non-IRIS controls (Fig. 1A). On the contrary, cyclooxygenase-1 (COX-1), interleukin-10 (IL-10), nucleotide-binding domain, leucine-rich repeat containing receptor (NLR) family pyrin domain containing 12 (NLRP12/Pypaf-7), and S100 calcium-binding protein A9 (S100A9) were significantly more abundant in the patients with IRIS than in the non-IRIS controls at 2 weeks of ART.

F1
FIGURE 1.:
Gene expression analysis in PBMCs from patients with HIV-associated TB-IRIS and HIV/TB coinfected controls without clinical IRIS. A, 100 ng of total RNA was used to obtain values for gene expression analysis using nCounter technology. Unsupervised hierarchical clustering of transcript abundance data from TB-IRIS (pink) (n = 17) and non-IRIS (blue) (n = 17) patients at week 2/IRIS-time point was performed using a heatmap in Qlucore Omics Explorer v3.2. The columns represent patients, whereas the rows are genes identified as discriminatory (P < 0.05, q < 0.1). Relative gene expression compared with the entire cohort was classified as low (green) and high (red), respectively. Genes were ordered according to their R statistic between IRIS and non-IRIS patients. B, Discriminatory genes were visualized on a PCA plot. The genes (variables) were colored according to their R statistic; green for the lowest (implying greater abundance in non-IRIS versus IRIS) and red for the highest (implying greater abundance in IRIS versus non-IRIS). The genes with the highest expression in IRIS were COX-1, IL-10, NLRP12, and S100A9. ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD); CD, cluster of differentiation; COX-1/PTGS, cyclooxygenase-1/prostaglandin-endoperoxide synthase; CTLA4, cytotoxic T lymphocyte-associated protein 4 (CD152); GATA3, glycine, alanine, thymine, alanine binding protein 3; ICOS, inducible T-cell costimulator; IFN-ϒ, interferon gamma; IL, interleukin; IL-7R, interleukin-7 receptor; ITK, interleukin-2-inducible T-cell kinase; pypaf-7, PYRIN-containing Apaf-1-like proteins; S100A9, S100 calcium-binding protein A9; Tbet, T-box transcription factor; TRAC, T-cell receptor alpha constant; TRAV, T-cell receptor alpha variable; TRBC, T-cell receptor beta constant; TRBV, T-cell receptor beta variable; TRDV, T-cell receptor delta variable; TRGC, T-cell receptor gamma constant; TRGV; T-cell receptor gamma variable.

PCA was then used to detect correlation patterns within the discriminating transcripts. The 4 genes (COX-1, δ = 0.96, fc = 1.9, R = 0.38, P = 0.025, q = 0.051; IL-10, δ = 0.75, fc = 1.7, R = 0.35, P = 0.045, q = 0.077; NLRP12, δ = 1.27, fc = 2.4, R = 0.40, P = 0.018, q = 0.042; and S100A9, δ = 1.10, fc = 2.1, R = 0.52, P = 0.002, q = 0.018), which were more abundant in patients with IRIS versus non-IRIS controls clearly correlated with each other and separated from the other transcripts (Fig. 1B).

Next, we quantitatively analyzed these 4 transcripts using the log2 transformed nCounter gene expression values. As shown in Supplemental Digital Content Figure 3, https://links.lww.com/QAI/B91, S100A9 expression significantly increased at the 2-week time point in the patients with IRIS (median log2 expression, 16.07; IQR, 15.15–16.35) from ART initiation (median, 14.59; IQR, 14.06–15.22) and was higher at 2 weeks compared with the controls (median, 15.05; IQR, 14.12–15.50; P = 0.002). NLRP12 expression also significantly increased from ART initiation (median, 5.66; IQR, 4.12–6.77) to the 2-week time point in patients with TB-IRIS (median, 6.94; IQR, 6.23–7.68), when it was higher compared with the controls (median, 6.15; IQR, 5.44–6.93; P = 0.016). IL-10 significantly decreased in controls from ART initiation (median, 7.56; IQR, 6.42–7.73) to 2 weeks (median, 6.41; IQR, 5.38–7.02; P = 0.005), and significantly greater IL-10 expression was seen in the patients with IRIS (median, 6.83; IQR, 6.33–8.02) versus controls (median, 6.41; IQR, 5.38–7.02; P = 0.049) at 2 weeks. Significantly higher COX-1 expression was also seen in the IRIS group (median, 8.93; IQR, 7.87–9.51) versus the non-IRIS controls (median, 7.94; IQR, 6.95–8.81; P = 0.049) at the 2-week time point.

TB-IRIS Is Characterized by Neutrophilia

The most upregulated gene in TB-IRIS identified in our expression analysis was S100A9, which is implicated in neutrophil accumulation in TB.21 Similarly, NLRP12 (Pypaf-7) is crucial for neutrophil recruitment in other models of infection,22 including to the lungs,23 whereas (among its other actions) COX-1 generates eicosanoids, which activate neutrophils.24 We have also shown that neutrophil markers strongly colocalise with IL-10 in human tuberculous granulomas.20 Our gene expression data, therefore, suggested a role for neutrophils in TB-IRIS pathogenesis and we examined this in another patient cohort, subsequently recruited in Cape Town. Supplemental Digital Content Table 1, https://links.lww.com/QAI/B91 details participant characteristics.

The patients with IRIS in both cohorts demonstrated an increase in peripheral neutrophil counts from ART initiation to the IRIS time point/week 2 [cohort 1 median (IQR) 1.77 (1.04–2.37) × 109/L to 2.91 (2.29–5.56) × 109/L, P = 0.049, Figure 2A; and cohort 2 median (IQR) 2.45 (1.48–4.00) × 109/L to 5.00 (3.35–7.23) ×109/L, P = 0.001, Figure 2B]. There were no changes in non-IRIS controls from ART initiation to 2 weeks. At 2 weeks, patients with IRIS in cohort 1 had significantly higher neutrophil counts versus the controls [median (IQR) 2.91 (2.29–5.56) × 109/L and median (IQR) 1.70 (0.97–2.52) × 109/L, respectively, P = 0.003, Figure 2A].

F2
FIGURE 2.:
Patients with TB-IRIS exhibit a rise in neutrophil count after 2 weeks of ART. A, Neutrophil counts from TB-IRIS (n = 10 at ART initiation and n = 17 at W2) and non-IRIS (n = 12 at ART initiation and n = 17 at W2) patients (cohort 1) are presented at ART initiation and at the week 2 (W2) time point. B, Neutrophil counts from TB-IRIS (n = 18 at ART initiation and n = 16 at W2) and non-IRIS (n =11 at ART initiation and n = 10 at W2) patients (cohort 2) are presented at initiation of ART and at week 2 (W2). Mann–Whitney and Wilcoxon tests were used (*P < 0.05, **P < 0.01).

There were no differences between patients with IRIS and controls' total lymphocyte or monocyte counts at either baseline or at the 2-week/IRIS time point.

Patients With TB-IRIS Demonstrate Activation of Neutrophils, as Defined by Surface Marker Expression

Neutrophil cell surface activation markers (CD11b, CD16, CD62L, and CD66a,c,e) were analyzed in whole blood from a subset of patients in cohort 2 (n = 6 per group) using flow cytometry. There was a significant linear trend toward decreased expression of CD62L, as defined by median fluorescence intensity, on the neutrophils of patients with TB-IRIS over the first 4 weeks from ART initiation (P = 0.014), with a significant difference between neutrophil CD62L expression at ART initiation (mean, 3881; SD, 2746) versus 4 weeks (mean, 1229; SD, 483; P = 0.042; Fig. 3A). Significantly higher expression of CD62L was observed in non-IRIS controls (mean, 3422; SD, 1196) compared with patients with TB-IRIS (mean, 1269; SD, 483; P = 0.005; Fig. 3A) at week 4, consistent with significantly increased CD62L expression on non-IRIS controls' neutrophils from ART initiation (mean, 1596; SD, 427) to 2 weeks (mean, 2387; SD, 517; P = 0.003) and further to 4 weeks (mean, 3422; SD, 1196; P = 0.009; Fig. 3A). Supplemental Digital Content Figure 2B, https://links.lww.com/QAI/B91 presents representative CD62L MFI at the week 2/IRIS time point.

F3
FIGURE 3.:
Neutrophil activation in patients with TB-IRIS and non-IRIS controls: The median fluorescence intensity of CD62L (A), CD16 (B), CD11b (C), and CD66a,c,e (D) on neutrophils in fresh whole blood is shown for patients with TB-IRIS (red, n = 6) and non-IRIS controls (black, n = 6 at ART initiation (W 0), n = 4 at W2, and n = 3 at W4). Lines represent mean values and P values (*P < 0.05, **P < 0.01) were derived from unpaired and paired t tests.

A similar pattern was seen for CD16 expression (Fig. 3B), although comparisons did not reach statistical significance. Median fluorescence intensity of CD11b decreased in the control group from ART initiation (mean, 12,130; SD, 4253) to week 4 (mean, 5562; SD, 2584; P = 0.047; Fig. 3C) but no difference was seen in the IRIS group. No differences were seen in CD66a,c,e expression (Fig. 3D) or in IL-8 RA (data not shown).

Patients With TB-IRIS Exhibit Increased Neutrophil Elastase and HNP 1–3 Plasma Concentrations

Neutrophil elastase is implicated in inflammation and tissue damage,25 and we measured this marker in plasma samples from cohort 2. Neutrophil elastase concentration increased significantly in patients with TB-IRIS between ART initiation (median 154 ng/mL; IQR, 122.5–191.3) and week 2 (median 274 ng/mL; IQR, 228–324; P = 0.0004; Fig. 4A). At 2 weeks after ART initiation, there was a significantly higher plasma neutrophil elastase concentration in patients with TB-IRIS compared with non-IRIS controls (median, 274 ng/mL; IQR, 228–324 versus median, 175 ng/mL; IQR, 119–253 P = 0.005; Fig. 4A).

F4
FIGURE 4.:
Analysis of plasma levels of neutrophil elastase and HNP1-3 in patients with TB-IRIS and non-IRIS controls. A, Neutrophil elastase [patients with TB-IRIS (red, n = 18 at ART initiation and n = 15 at W2) and non-IRIS controls (black n = 11)] plasma concentrations were quantified using enzyme-linked immunosorbent assay in cohort 2. B, HNP 1–3 [(patients with TB-IRIS (red, n = 18 at ART initiation and n = 16 at W2) and non-IRIS controls (black n = 11)] plasma concentrations were quantified using enzyme-linked immunosorbent assay in cohort 2. C, HNP 1–3 plasma concentrations were quantified using enzyme-linked immunosorbent assay in cohort 1 [patients with TB-IRIS (n = 15 at ART initiation and n = 16 at W2) and non-IRIS controls (n = 8)]. Lines represent medians and P values (**P < 0.01, ***P < 0.001) were derived from Mann–Whitney and Wilcoxon tests.

Analysis of plasma HNP 1–3 concentrations in cohort 2 revealed an increase in patients with TB-IRIS from ART initiation (median, 0 pg/mL; IQR, 0–1775) to the week-2 time point (median, 2675 pg/mL; IQR, 990–11,353; P = 0.005; Fig. 4B). In cohort 1, HNP1-3 concentrations also increased from week 0 (median, 7153 pg/mL; IQR, 5998–8896) to week 2 (median, 13,821 pg/mL; IQR, 7271–22,975; P = 0.001), when they were higher compared with controls (median, 7510 pg/mL; IQR, 6007–8751; P = 0.038; Fig. 4C).

Analysis of a wider cohort recruited identically in Uganda confirmed significant differences in HNP concentration between patients with TB-IRIS and non-IRIS controls at the IRIS time point/week 2, with resolution of these differences by later time points (Supplemental Digital Content Figure 4, https://links.lww.com/QAI/B91).

LN Granulomas From Patients With IRIS Show Significant Neutrophil Infiltration and IL-10 Production

We proceeded to characterize neutrophil infiltration and accumulation in LNs of patients with TB-IRIS in situ using immunohistochemistry. There was intense staining in the center of the biopsies for the neutrophil marker CD15, correlating with areas of significant necrosis (Fig. 5). LNs from patients with TB-IRIS also stained strongly for IL-10, largely correlating with neutrophils, as previously shown.20

F5
FIGURE 5.:
Neutrophil infiltration in the LNs of patients with TB-IRIS. Caseous granulomas from consecutive cross-sectional LN sections of patients with TB-IRIS (n = 3) that were stained with Hematoxylin and Eosin (H&E) (A), CD15 (neutrophils, B), or IL-10 (C). Intense neutrophil staining localizes within most of these caseous granulomas. IL-10 staining was diffuse but did localize within and near caseous granulomas. Black bars represent 200 µm.

DISCUSSION

TB-IRIS immunopathogenesis remains incompletely defined and a lack of predictive markers makes its diagnosis and treatment complex. Given the temporal association of IRIS with reconstitution of CD4+ T lymphocyte numbers on ART, many studies have focused on Th1 cells.26,27 However, TB-IRIS is not explained simply by a change in CD4 numbers, and innate cells are also implicated in the syndrome.5,12 Neutrophils are increasingly recognized in TB pathology,28–30 as we have described in TB-meningitis IRIS,6 but they had not previously been studied in this detail.

We recruited patients with HIV+TB+ at risk of developing IRIS (cohort 1) and investigated transcript abundance of genes relating to inflammasome, T-cell receptor, cytokines, and their receptors. The gene transcripts that were most abundant in patients with IRIS versus non-IRIS controls, and clearly discriminatory on a PCA plot, were S100A9, IL-10, NLRP12, and COX-1. Increased expression of inflammasome and neutrophil-associated genes in TB-IRIS is consistent with previous results,12,31 but the lower abundance of TCR-associated genes in patients with TB-IRIS was unexpected and deserves further analysis. This may reflect poor reconstitution of normal T-cell function in TB-IRIS and again supports the concept that the phenomenon is driven by innate inflammation without an orchestrated acquired immune response.

Among the more abundant transcripts, S100A9 contributes to inflammation in TB because of its role in neutrophil recruitment6,21,32 and it has been proposed as a promising biomarker for TB diagnosis.33,34 NLRP12 also plays an important role in neutrophil recruitment.22,23 We have reported increased levels of the IL-10 cytokine family in IRIS17 and observed significant IL-10 staining in tuberculous granulomas where it associates with neutrophil markers and necrosis.20 The source of IL-10 in TB-IRIS remains unclear, with conflicting data on whether regulatory T-cell populations are expanded (reviewed in Ref. 4). Again, it may be that innate cells are responsible for the production of immunosuppressive cytokines. Gene expression data, therefore, suggested a role of neutrophils in the development of TB-IRIS and we recruited a further cohort to perform neutrophil functional assays.

In both cohorts, we first demonstrated that patients meeting INSHI criteria for IRIS exhibited an increase in neutrophil count from ART initiation. We observed that neutrophils accumulate intensely at sites of disease in TB-IRIS and associate with areas of necrosis. The neutrophils of the patients with IRIS were activated, shedding their CD62L/L-selectin over time with a significant drop from ART initiation to 4 weeks (despite the initiation of corticosteroids in 3 patients); the reverse pattern being observed in controls. A similar trend to CD62L was seen for CD16. We have previously shown that at ART initiation, neutrophils in antiretroviral-naive HIV-infected patients are activated, rapidly undergo cell death, and their ability to kill M. tuberculosis is impaired compared with HIV-uninfected controls.18 Our data confirms that abnormal activation is reversed on ART in patients with an uncomplicated clinical course (undergoing protective immune reconstitution), whereas in IRIS, the neutrophil dysfunction becomes exaggerated (these patients undergo pathogenic immune reconstitution).

We did not see differences between the groups in other activation markers, including CD11b and CD66a,c,e. However, loss of CD16 and CD62L occurs preferentially as neutrophils progress to cell death.35 Collectively, these data suggest that neutrophil activation and presumably early cell death is a hallmark of TB-IRIS.28,30 Increased neutrophil influx and death at disease sites will lead to release of cytotoxic granule contents causing local tissue damage and amplifying inflammatory responses,29,36 consistent with necrotic abscesses and lymphadenopathy often observed in TB-IRIS.

Compatible with this conclusion, we found an increased neutrophil elastase concentration in the plasma of patients with TB-IRIS versus non-IRIS controls 2 weeks after initiation of ART in cohort 2. There was also an increase from ART initiation in the elastase concentration of the South African patients with TB-IRIS , and an increase in HNP 1–3 in both cohorts. The difference in neutrophil elastase concentration between patients with IRIS and controls was seen despite no significant difference in absolute neutrophil count in cohort 2, suggesting that plasma concentrations of this granule product might represent more than simply a higher number of circulating neutrophils.

Notably, some activation parameters in the patients developing IRIS tended to be less abnormal at ART initiation. This is consistent with observations by others14,37,38 that TB-IRIS may be heralded by lower cytokine concentrations at ART initiation but subsequent large magnitude changes.

Limitations of our study include relatively small group sizes. We were unable to perform neutrophil functional assays including phagocytosis, mycobacterial killing, and cell death in sufficient numbers because few samples met our stringent prespecified neutrophil purity and viability criteria of >90%. Differences in HNP concentrations between the cohorts might be due to differences in preanalytical handling; in cohort 1, blood was collected in Uganda and assays performed in Belgium, whereas South African samples were analyzed locally. We also note a difference in neutrophil and CD4 counts between the 2 cohorts, likely to reflect the clinical realities of treating HIV-TB coinfection in Uganda in 2009 compared with South Africa in 2013, as well as differences in analysis platforms and racial background. However, the fact that we could demonstrate a role for neutrophils in 2 geographically different cohorts increases the generalizability of our findings.

A strength of our analysis was the inclusion of both peripheral blood and LN samples, although longitudinal analyses were conducted exclusively in peripheral blood, which may not be representative of the tissue environment. However, because peripheral blood does exhibit significant perturbations in TB-IRIS, is easily accessible for serial measurements, and contains many components of both the innate and acquired immune systems, we believe that analysis of this compartment is informative.

In conclusion, our data suggest that TB-IRIS is characterized by aberrant immunological recovery with inflammasome activation and neutrophil recruitment instead of reconstitution of normal T-cell receptor function. Within the context of local and systemic inflammation, recruited neutrophils are activated, are likely to undergo rapid cell death, and will release cytotoxic granule contents. This drives tissue damage and further inflammation, paradoxically associated with immunosuppressive IL-10 release, which may compromise host control of any remaining viable mycobacteria. Because neutrophils are likely to be key effector cells mediating pathological damage in TB-IRIS, it seems logical to consider host-directed therapies to reduce neutrophil recruitment (eg, CXCR2 inhibitors39 and anti-C5a inhibitors40) or to promote neutrophil apoptosis (eg, statins41);however, these questions require further research.

ACKNOWLEDGMENTS

The authors thank Prof. Jon Friedland and Prof. Paul Elkington for their expert input into the design and supervision of the tissue destruction in tuberculosis 2 study in Cape Town, from which our patients were recruited.

REFERENCES

1. Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015;10:1077–1099.
2. Bana TM, Lesosky M, Pepper DJ, et al. Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors. BMC Infect Dis. 2016;16:518.
3. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516–523.
4. Lai RP, Meintjes G, Wilkinson RJ. HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopathol. 2016;38:185–198.
5. Lai RP, Nakiwala JK, Meintjes G, et al. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol. 2013;43:1995–2002.
6. Marais S, Wilkinson KA, Lesosky M, et al. Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2014;59:1638–1647.
7. Ravimohan S, Tamuhla N, Kung SJ, et al. Matrix metalloproteinases in tuberculosis-immune reconstitution inflammatory syndrome and impaired lung function among advanced HIV/TB co-infected patients initiating antiretroviral therapy. EBioMedicine. 2016;3:100–107.
8. Tadokera R, Meintjes GA, Wilkinson KA, et al. Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol. 2014;44:127–136.
9. Wilkinson KA, Walker NF, Meintjes G, et al. Cytotoxic mediators in paradoxical HIV-tuberculosis immune reconstitution inflammatory syndrome. J Immunol. 2015;194:1748–1754.
10. Tran HT, Van den Bergh R, Loembe MM, et al. Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2013;27:1725–1734.
11. Andrade BB, Singh A, Narendran G, et al. Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS Pathog. 2014;10:e1004433.
12. Lai RP, Meintjes G, Wilkinson KA, et al. HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by toll-like receptor and inflammasome signalling. Nat Commun. 2015;6:8451.
13. Tan HY, Yong YK, Shankar EM, et al. Aberrant inflammasome activation characterizes tuberculosis-associated immune reconstitution inflammatory syndrome. J Immunol. 2016;196:4052–4063.
14. Goovaerts O, Jennes W, Massinga-Loembe M, et al. LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients. PLoS One. 2013;8:e81856.
15. Tadokera R, Meintjes G, Skolimowska KH, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J. 2011;37:1248–1259.
16. Tan HY, Yong YK, Andrade BB, et al. Plasma interleukin-18 levels are a biomarker of innate immune responses that predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2015;29:421–431.
17. Tadokera R, Wilkinson KA, Meintjes GA, et al. Role of the interleukin 10 family of cytokines in patients with immune reconstitution inflammatory syndrome associated with HIV infection and tuberculosis. J Infect Dis. 2013;207:1148–1156.
18. Worodria W, Menten J, Massinga-Loembe M, et al. Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection. Antivir Ther. 2012;17:841–848.
19. Lowe DM, Bangani N, Goliath R, et al. Effect of antiretroviral therapy on HIV-mediated impairment of the neutrophil antimycobacterial response. Ann Am Thorac Soc. 2015;12:1627–1637.
20. Diedrich CR, O'Hern J, Gutierrez MG, et al. Relationship between HIV-1 co-infection, IL-10, and M. tuberculosis in human lymph node granulomas. J Infect Dis. 2016;214:1309–1318.
21. Gopal R, Monin L, Torres D, et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am J Respir Crit Care Med. 2013;188:1137–1146.
22. Cai S, Batra S, Del Piero F, et al. NLRP12 modulates host defense through IL-17A-CXCL1 axis. Mucosal Immunol. 2016;9:503–514.
23. Ulland TK, Jain N, Hornick EE, et al. Nlrp12 mutation causes C57BL/6J strain-specific defect in neutrophil recruitment. Nat Commun. 2016;7:13180.
24. Hinz C, Aldrovandi M, Uhlson C, et al. Human platelets utilize Cycloxygenase-1 to generate dioxolane A3, a neutrophil-activating eicosanoid. J Biol Chem. 2016;291:13448–13464.
25. Gehrig S, Duerr J, Weitnauer M, et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Am J Respir Crit Care Med. 2014;189:1082–1092.
26. Bourgarit A, Carcelain G, Samri A, et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J Immunol. 2009;183:3915–3923.
27. Meintjes G, Wilkinson KA, Rangaka MX, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med. 2008;178:1083–1089.
28. Lowe DM, Bandara AK, Packe GE, et al. Neutrophilia independently predicts death in tuberculosis. Eur Respir J. 2013;42:1752–1757.
29. Lowe DM, Redford PS, Wilkinson RJ, et al. Neutrophils in tuberculosis: friend or foe? Trends Immunol. 2012;33:14–25.
30. Ong CW, Elkington PT, Brilha S, et al. Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis. PLoS Pathog. 2015;11:e1004917.
31. Marais S, Lai RP, Wilkinson KA, et al. Inflammasome activation underlies central nervous system deterioration in HIV-associated tuberculosis. J Infect Dis. 2017;215:677–686.
32. Pruenster M, Kurz AR, Chung KJ, et al. Extracellular MRP8/14 is a regulator of beta2 integrin-dependent neutrophil slow rolling and adhesion. Nat Commun. 2015;6:6915.
33. Zhou J. Early diagnosis of pulmonary tuberculosis using serum biomarkers. Proteomics. 2015;15:6–7.
34. Xu D, Li Y, Li X, et al. Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-dimensional LC-MS/MS. Proteomics. 2015;15:58–67.
35. Hart SP, Ross JA, Ross K, et al. Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000;7:493–503.
36. Korbel DS, Schneider BE, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 2008;10:995–1004.
37. Ravimohan S, Tamuhla N, Steenhoff AP, et al. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. Lancet Infect Dis. 2015;15:429–438.
38. Goovaerts O, Jennes W, Massinga-Loembe M, et al. Lower pre-treatment T cell activation in early- and late-onset tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS One. 2015;10:e0133924.
39. De Soyza A, Pavord I, Elborn JS, et al. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J. 2015;46:1021–1032.
40. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol. 2011;48:1631–1642.
41. Thomson NC. Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis. 2016;10:211–234.
Keywords:

tuberculosis; HIV-1; neutrophils; immune reconstitution inflammatory syndrome; IRIS

Supplemental Digital Content

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.